IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

A REVIEW ON MICROSPONGE DRUG DELIVERY SYSTEM

SHOBITH M.H, RAKSHITHA S.R, KEERTHI H.N, VINAY S.V, ROBIN S,

HILLSIDE COLLEGE OF PHARMACY AND RESEARCH CENTER RAGHUVANAHALLI BENGALURU-560062, KARNATAKA

ABSTRACT

Patented, largely cross-linked, pervious, polymeric microspheres, polymeric system conforming of pervious microspheres that can entrap wide range of actives and also release them into the skin over time and in response to detector" is the description of a microsome delivery system (MDS). 10 – 25 microns in periphery. For a range of skin treatments, the capacity to load a wide range of active constituents into micro-sponge polymers provides enhanced product efficacity, mildness, tolerability, and extended wear and tear. Several dependable and harmonious ways for systemic medicines were developed under the general title of transdermal delivery systems (TDS), which employ the skin as a gate of entry. The safety and efficacity of several medicines have increased lately. generally, the sphere's outside contains pores that allow rudiments to continuously leave the sphere. Microsponges, which are pervious, polymeric microspheres primarily intended for topical use, have set up a new purpose in oral delivery.

KEYWORD: Micro sponge, drug delivery system.

Fig 1: Structure of microsponges

INTRODUCTION:

There has been a lot of interest lately in developing new microsponge- grounded medicine delivery systems to regulate and modify the release of medicinals. By adding the drug to a carrier system, the remedial indicator and duration of pharmacological exertion can be altered. Because topical results with factors like vitamins and α-hydroxy acids can offer apparent and empirical goods, especially for growing or photodamaged skin, their growing fashionability has sparked consumer interest in skin care and treatment goods. [(1)] Experimenters from each around the world are looking into microparticulate medicine delivery styles as medicine carriers due to their advantages. This in turn led to the development of microsponges in 1988. [(2)] An effective and safe topical expression has notable operations in treating a variety of diseases and clinical conditions because it reduces renal toxin, avoids gastrointestinal disturbances, eliminates acute toxin associated with the intravenous route, avoids or shortens hospitalization, lowers cure frequence, and increases patient satisfaction. [(3)] Microsponges are pervious, lymeric medicine systems conforming of microspheres with a large porosity face and bitsy, sponger- suchlike patches. The size range of microsponges is 5 µm to 300 µm, which is lower than the maturity of bacterial sizes. The typical severance size of microsponges is 0.25 µm, and their compasses range from 5 to 300 µm. This hinders their penetration because it's much lower than the typical size of certain bacteria. This explains why microsponges remain stable without the need of any kind of excipient and why they're known as tone- altering. [(4)]

MEDICATION OF MICROSPONGES

Liquid – liquid suspense polymerization:

generally, a result is created by combining monomers with the functional or active constituents that dissolve in water. This phase is also agitatedly suspended in an waterless phase, which generally contains composites similar as surfactants and dispersants to prop in suspense. Once the suspense has distinct driblets of the asked size, the monomers are actuated by catalysis, high temperature, or radiation to complete the polymerization process. A globular structure with hundreds of microsponges grouped like grapes forms as the polymerization process progresses, creating interconnected budgets. [(1)]



Figure 2: Response vessel for micro sponges medication by liquid- liquid suspense polymerization.

QUASI-EMULSION DETERGENT PROLIXITY

Micro sponges can be produced using the quasi-emulsion detergent prolixity process. To form an internal phase, a polymer, similar as ethyl cellulose or Eudragit RS100, is dissolved in an organic detergent.
The medicine is also dissolved into the polymer result by ultrasonication. The external phase, which comprises distilled water and polyvinyl alcohol, is also mixed with the inner phase after a reasonable period of time spent stirring constantly (Shah et al., 1989). Filtration is also used to insulate the micro sponges. [5]



Figure 3: Quasi emulsion solvent diffusion method

An internal phase conforming of 1 v/ v triethylcitrate and 5 ml of dichloromethane adulterated in 200 mg of Eudragit RS- 100.
Triethylcitrate (TEC) was also added to the polymer to increase its fluidity. The admixture was also agitated at 500 rpm while dicyclomine was added. After that, the admixture was introduced to the external phase, which was a 0.5 w/ v polyvinyl alcohol (PVA) waterless result. Microsponges formed as a result of dichloromethane sinking after eight hours of churning. The microsponge were sanctified with water, also filtered and dried at 40 °C for 12 hours. [6]

TABLE 1: Formulation

Ingredient	FDRS1	FDRS2	FDRS3	FDRS4
Dicyclomine (mg)	600	1200	1800	2400
Eudragit 100 (mg)	200	200	200	200

Triethylcitrate (mg)	1	1	1	1
Dichloromethane (ml)	5	5	5	5
PVA (0.5% w/v)	0.5	0.5	0.5	0.5

(7)

Table 2 : **METHODS FOR PREPARATION OF MICYS**

METHOD	ADVANTAGES	DISADVANTAGES
Liquid-liquid suspension polymerization	Can be suitably modified to one-step or two-step methods for drug loading	Probable entrapment of unreacted monomers and solvent traces. Non uniform structure. Takes a lengthy time for the monomers to react. Requires two step methods for thermosensitive drugs that has low drug loading efficiency.
Quasi-emulsion solvent diffusion	No monomer entrapment low solvent traces High drug loading No exposure of drug to easily controlled by controlling the stirring Spherical particles	Cannot be used for the loading of water-soluble drugs Takes a lengthy time for the monomers to react. The medication must dissolve in a volatile, water-soluble solvent.
w/o/w emulsion diffusion	Efficient for loading water-soluble drugs Can be used to entrap proteins and peptides	Uses water-insoluble surfactants that can be present as residues in the resultant Micsys
Addition of porogen	Highly porous structure with nicely distributed and interconnected pores.	May cause disruption

o/o emulsion solvent	No presence of surfactant traces in Micsys	Requires vigorous washing to remove the traces of organic solvents.

(8)

FEATURES OF THE MATERIALS ENCASED IN MICROSPONGE CONTAINERS:

• It must be entirely miscible in monomer or able of getting so with a little addition of a water- immiscible detergent.
• It needs to be water immiscible or slightly answerable.
• Since it should be inert to monomers, it should reply with other excipients in the expression.
• To avoid ornamental problems brought on by the solubility of the active substances, the maximum quantum of w/ w micro-sponges that can be added to the vehicle is 10 – 12. The auto will not be suitable to use the micro-sponges before they run out.
• Micro-sponges' globular structure shouldn't disintegrate. The active cargo and polymer design of the micro-sponges must be acclimated for the needed release rate within the given time range.
• When exposed to circumstances and a polymerization catalyst, it should always be stable. The process of polymerization. (9)

OPERATIONS OF MICROSPONGE SYSTEMS:

The globular can continually release rudiments since its surface is frequently pervious. Micro-sponges are pervious, polymeric microspheres that are substantially used topically, still they've lately been used orally as well. Micro-sponges are made to effectively deliver a pharmaceutical active ingredient at the smallest possible lozenge, alter drug release, improve stability, and decrease side effects. (10)

ACTIVE AGENTS	APPLICATION
anti-acne, for example. Benzoyl peroxide	skin sensitization and irritation without sacrificing efficacy.
inflammatory-reducing drugs, such as hydrocortisone	prolonged action with a decrease in dermatomes and skin allergic response.
antifungal	continuous release of active ingredients.
Antidandruff products, such as selenium sulfide and zinc pyrithione	longer safety and efficacy, less irritation, and a less disagreeable smell.
Antiprurities	improved and prolonged activity.
skin-depigmenting agent, such as hydroquinone	improved stability against oxidation and increased efficacy and aesthetic appeal.
Rubefacients	extended activity with less odor, grease, and irritation.

SAFETY PARAMETERS:

Determining the safety of microsponges was needed, despite the fact that they're made of polymers that are n't physiologically active. being apprehensive of further than thirty distinct safety factors. Studies on guinea gormandizer mislike responses, rabbit eye vexation, bacterial mutagenicity, rat oral toxin, and rabbit skin vexation constantly show that microsponges are inoffensive. (11)

Microsponge- grounded Delivery Systems for Drug driving

Applying topical drug using microsponge technology Using an conflation detergent prolixity fashion, benzoyl peroxide was delivered microspongically by introducing an organic internal phase including benzoyl peroxide, ethyl cellulose, and dichloromethane into a stirred waterless phase containing polyvinyl alcohol. (12) and by use of styrene and divinyl benzene suspense polymerization. (13) Compared to the bone that contained free BPO, the entrapped system released the medication more slowly. The development of a topical delivery method with less irritation was accomplished. (14)(15)

A new expression containing 0.15 retinol contained in microsponge budgets was created in order to lessen skin vexation, extend treatment exposure, and release hydroquinone (HQ) 4 gradationally. The efficacity and safety of this product were estimated in a 12- week open- marker study. Both retinol 0.15 and HQ 4 were set up to be safe and effective in an open- marker trial. (16) It was shown that applying fluconazole gel topically via a microspongic system could extend the release (17) An MDS system for retinoic acid was examined for medicine release andanti-acne efficacity. Larger, statistically significant reductions in seditious andnon-inflammatory lesions were achieved when tretinoin was trapped in the microsponge. (18) A microsponge ® is used to apply topical analgesic,anti-inflammatory, andcounter-irritant medicines for the musculoskeletal system. (19)

Using microsponge technology to administer medicines orally It has been shown that the microsponge system can quicken the solubilization of medicines that are inadequately water answerable in oral operations by enmeshing them in its pores. The drug is efficiently reduced to nanosecond patches due to the bitty pores, and the substantial increase in face area pets up the solubilization process. By altering the intraparticle viscosity of ibuprofen microsponges, Eudragit RS, an acrylic polymer, enables regulated oral administration. (20) A prolonged release expression of chlorpheniramine maleate for oral medicine delivery is created using greasepaint- carpeted microsponges and a dry impact mixing fashion. (21) Eudragit RS 100 was used in thequasi-emulsion detergent prolixity process to produce ketoprofen for regulated oral administration.

The microsponge tablets were also made by direct contraction. The results indicated a significantly bettered compressibility when the drug and polymer were physically mixed. This redounded from the microsponge structure's plastic distortion, which created mechanically robust tablets and recalled a sponger. (22) Using a marketable Microsponge ® 5640 device, flurbiprofen was delivered in a controlled, colon-specific manner. When an enzyme was added to contraction- carpeted colon-specific tablet phrasings, in vitro studies showed that the medicine released in agreement with a modified release pattern at the eighth hour, which matched the proximal colon appearance time. still, when the enzyme was added at the eighth hour, medicine release from phrasings created using severance-plugging microsponges showed an increase in medicine release. (23)

MICROSPONGE- GROUNDED DELIVERY SYSTEMS FOR BONE AND TOWEL ENGINEERING:

To make bone- cover composites, two waterless dissipations ofa-tricalcium phosphate grains and maquillages of calcium-deficient hydroxyapatite were mixed withpre-polymerized polymethylmethacrylate maquillages and liquid methylmethacrylate monomer. The final mixes sounded pervious and performed as microsponges. Grounded on the biodegradation of the sponger matrix, the introductory fibroblast growth factor(bFGF) integrated into a collagen

sponger distance was released in the mousesub-cutis and shown cure-dependent original angiogenic exertion. In the mouse ischemic hind leg, intramuscular injection of collagen microsponges containing bFGF redounded in a substantial increase in blood inflow that would not have been possible with gelcap injection of bFGF. These findings point to the significance and implicit remedial benefits of type I collagen as a bFGF force. [24]

In agreement with the biodegradation of the sponger matrix, a collagen sponger distance containing introductory fibroblast growth factor(bFGF) was released in the mousesub-cutis and showed cure-dependent original angiogenic exertion. The significant increase in blood inflow that was convinced in the ischemic mouse's hind branch following intramuscular injection of collagen microsponges carrying bFGF could n't have been caused by the gelcap infusion of bFGF. These results punctuate the significance of type I collagen as a bFGF force and its possible remedial operations. [25] A biodegradable graft material made of collagen microsponge was developed to prop in the rejuvenescence of autologous roadway towel during cardiovascular towel grafting. [26]

A thin biodegradable mongrel mesh made of synthetic poly (DL- lactic-co-glycolic acid) (PLGA) and naturally being collagen was used for a three- dimensional culture of mortal skin fibroblasts. The mongrel mesh was created by using web- suchlike collagen microsponges made from the orifices of the PLGA- knitted mesh. [27] Our collagen-microsponge and biodegradable polymer- finagled patch showed good in situ rejuvenescence at the venous and arterial wall, suggesting that it might be used as a new surgical material for the form of the cardiovascular system. [28]

CONCLUSION:

In conclusion, medicine delivery technologies that employ microsponges have shown a great deal of pledge for transubstantiating the medicine delivery assiduity. Because of their multitudinous benefits, including targeted dissipation, bettered stability, and controlled release, are handed by these small polymeric spheres with a special porosity structure. Microsponges offer the stylish possible remedial efficacity by boxing specifics inside their structure, precluding them from demeaning. likewise, they've a great deal of pledge for personalized treatment due to their capacity to access deeply into apkins and deliver medicines precisely where they're demanded. The operation of microsponges in medicine delivery systems will really be essential to enhancing patient issues and creating new prospects for the pharmaceutical lores as exploration progresses.

ACKNOWLEDGEMENT:

We wish to express our sincere gratitude to Dr. S.N. Sriharsha, M Pharm, PhD., Professor and Principal of Hillside college of pharmacy and Research Centre, Bengaluru for providing us the opportunity to perform our project work. We thank our Head of the Department, Department of pharmacy practice, Hillside College of pharmacy and Research center, Bengaluru, prof. Dr. K. Jesindha Beyatricks., M Pharm, PhD, for providing us with his insights. Our sincere thanks to our guide, ***Dr Lokesh S V****, Asst Professor, Department of Pharmacy Practice, Hillside college of Pharmacy and Research Centre, Bengaluru for his help and guidance in our thesis. For help and guidance, encourage, taking more responsibility, about our project.*

Financial Support and sponsorship:

None.

Conflict of interest:

None.

Reference

REFRENCES

1. Kaity S, Isaac J, Ghosh A. Interpenetrating polymer network of locust bean gum-poly (vinyl alcohol) for controlled release drug delivery. Carbohydrate polymers. 2013 Apr 15;94(1):456-67.
2. Srivastava R, Pathak K. Microsponges: a futuristic approach for oral drug delivery. Expert opinion on drug delivery. 2012 Jul 1;9(7):863-78.
3. Osmani RA, Aloorkar NH, Ingale DJ, Kulkarni PK, Hani U, Bhosale RR, Dev DJ. Microsponges based novel drug delivery system for augmented arthritis therapy. Saudi pharmaceutical journal. 2015 Oct 1;23(5):562-72.
4. Bobade PS, Ganorkar SB, Baviskar PN, Patil NB, Shinde DB, Shirkhedkar AA, Chalikwar SS. Pharmaceutical Analysis of Berberine: An Update. Separation & Purification Reviews. 2024 Nov 19:1-0.
5. Hibah Aldawsari HA, Badr-Eldin SM. Microsponges as promising vehicle for drug delivery and targeting: preparation, characterization and applications.
6. Jain R, Parmar R, Jain NK. Evalution Of Insecticidal Activity Of Cassia Tora L.(Leaves) Tablet Against Tribolium Castaneum Context With Preservation Of Brown Rice.
7. Tiwari A, Mishra MK, Shukla A, Yadav SK. Microsponge: An augmented drug delivery system. American Journal of PharmTech Research. 2016;6(6):79-95.
8. Kumari A, Jain A, Hurkat P, Verma A, Jain SK. Microsponges: a pioneering tool for biomedical applications. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2016;33(1).
9. Forster C, Sagade J. Women's human rights in India. Routledge India; 2019 Aug 28.
10. Khalid M, Kumar S. An Overview of New Methods for Designing, Formulating, and Characterising Herbal Microsponges. J Emerg Technol Innov Res. 2023;10(8):47-57.
11. Yousif NZ, Salman ZD. Microsponge as a Strategy for Effective Drug Delivery System. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2023 Jul 20;23(3):322-35.
12. Yazici E, Kas HS, Hincal AA. Microsponges. Farmasotik Bilimler Dergisi (Turkey). 1994;19(3):121-8.
13. Wester RC, Patel R, Nacht S, Leyden J, Melendres J, Maibach H. Controlled release of benzoyl peroxide from a porous microsphere polymeric system can reduce topical irritancy. Journal of the American Academy of Dermatology. 1991 May 1;24(5):720-6.
14. Atri V, Kaushik D, Kamra M. A CONCISE REVIEW: MICROSPONGE AS GEL.
15. Disouza JI, Saboji JK, Jyothi MH, Patil CS. In-vitro antibacterial and skin irritation studies of microsponges of benzoyl peroxide. INDIAN DRUGS-BOMBAY-. 2001;38(7):361-2.
16. Fincham JE, Karnik KA. Patient counseling and derm therapy. US Pharmacist. 1994;19(4):56-83.
17. D'souza JI, Masvekar RR, Pattekari PP, Pudi SR, More HN. Microspongic Delivery Of Fluconazole For Topical Application, 1st Indo-Japanese International Conference On Advances In Pharmaceutical Research And Technology. Mumbai, India. 2005:25-9.

18. Grimes PE. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis. 2004 Dec 1;74(6):362-8.
19. Embil VP. OTC External analgesic cream/topical analgesic-anti-inflammatory, counterirritant utilizing the Microsponge Delivery System (MDS) for controlled release of actives. UK Patent. 2000;1010586.
20. KAWASHIMA Y, NIWA T, TAKEUCHI H, HINO T, ITO Y. Control of prolonged drug release and compression properties of ibuprofen microsponges with acrylic polymer, Eudragit RS, by changing their intraparticle porosity. Chemical and pharmaceutical bulletin. 1992 Jan 25;40(1):196-201.
21. ARITOMI H, YAMASAKI Y, YAMADA K, HONDA H, KOISHI M. Development of sustained-release formulation of chlorpheniramine maleate using powder-coated microsponge prepared by dry impact blending method. 1996 Mar 20;56(1):49-56.
22. Çomoğlu T, Gönül N, Baykara T. Preparation and in vitro evaluation of modified release ketoprofen microsponges. Il farmaco. 2003 Feb 1;58(2):101-6.
23. Orlu M, Cevher E, Araman A. Design and evaluation of colon specific drug delivery system containing flurbiprofen microsponges. International journal of pharmaceutics. 2006 Aug 2;318(1-2):103-17.
24. Chen G, Ushida T, Tateishi T. A biodegradable hybrid sponge nested with collagen microsponges. Journal of Biomedical Materials Research: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials. 2000 Aug;51(2):273-9.
25. Kanematsu A, Marui A, Yamamoto S, Ozeki M, Hirano Y, Yamamoto M, Ogawa O, Komeda M, Tabata Y. Type I collagen can function as a reservoir of basic fibroblast growth factor. Journal of controlled release. 2004 Sep 30;99(2):281-92.
26. Iwai S, Sawa Y, Ichikawa H, Taketani S, Uchimura E, Chen G, Hara M, Miyake J, Matsuda H. Biodegradable polymer with collagen microsponge serves as a new bioengineered cardiovascular prosthesis. The Journal of Thoracic and Cardiovascular Surgery. 2004 Sep 1;128(3):472-9.
27. Chen G, Sato T, Ohgushi H, Ushida T, Tateishi T, Tanaka J. Culturing of skin fibroblasts in a thin PLGA–collagen hybrid mesh. Biomaterials. 2005 May 1;26(15):2559-66.
28. Iwai S, Sawa Y, Taketani S, Torikai K, Hirakawa K, Matsuda H. Novel tissue-engineered biodegradable material for reconstruction of vascular wall. The Annals of thoracic surgery. 2005 Nov 1;80(5):1821-7.